Skip to search formSkip to main contentSkip to account menu

cenicriviroc

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cenicriviroc (CVC) is a first-in-class dual CCR2/5 antagonist with potent anti-inflammatory and antifibrotic properties. The 1… 
2019
2019
Background and aim The hepatitis C virus (HCV) is a single-strand RNA virus that infects millions of people worldwide. Recent… 
2019
2019
Acute graft-versus-host disease (aGVHD) is one of the major complications after liver transplantation (LTx), which is induced by… 
2019
2019
NAFLD is a wide spectrum disease ranging from simple steatosis, NASH to liver cirrhosis and is the most common type of CLD in the… 
2017
2017
The search goes on for effective medical treatment of nonalcoholic steatohepatitis (NASH). The following are phase IIb trial… 
2015
2015
ZusammenfassungDie Leberfibrose, d. h. die bindegewebige Vernarbung der Leber, stellt die gemeinsame Endstrecke chronischer… 
2014
2014
Cenicriviroc (CVC), a once‐daily, dual CCR5/CCR2 co‐receptor antagonist, has completed Phase 2b development. CVC demonstrated… 
2014
2014
There are 28 approved antiretroviral drugs for the treatment of HIV infection; combinations of these drugs clearly change the…